"Ki-67 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.
| Descriptor ID |
D019394
|
| MeSH Number(s) |
D12.776.660.625.500 D23.050.290.500 D23.101.140.400
|
| Concept/Terms |
Ki-67 Antigen- Ki-67 Antigen
- Antigen, Ki-67
- Ki 67 Antigen
- Antigen Ki-67
- Antigen Ki 67
- Ki-67, Antigen
- MIB-1 Antigen
- Antigen, MIB-1
- MIB 1 Antigen
- MIB-1 Protein
- MIB 1 Protein
- Antigen Ki67
- Ki67, Antigen
|
Below are MeSH descriptors whose meaning is more general than "Ki-67 Antigen".
Below are MeSH descriptors whose meaning is more specific than "Ki-67 Antigen".
This graph shows the total number of publications written about "Ki-67 Antigen" by people in this website by year, and whether "Ki-67 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 1 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 2 | 2 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 2 | 3 |
| 2014 | 0 | 2 | 2 |
| 2015 | 2 | 3 | 5 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 3 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 3 | 3 |
| 2024 | 0 | 3 | 3 |
| 2025 | 1 | 1 | 2 |
| 2026 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ki-67 Antigen" by people in Profiles.
-
Surgical window of opportunity clinical trial of abemaciclib and letrozole for endometrioid adenocarcinoma of the endometrium. Gynecol Oncol. 2026 Aug; 211:171-177.
-
The Ki-67 proliferation index and recurrence risk of intracranial meningioma: a multicenter, retrospective cohort study of 5,050 patients. Acta Neurochir (Wien). 2026 04 06; 168(1).
-
Association of integrated biomarkers and progression-free survival prediction in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy. Theranostics. 2025; 15(13):6444-6453.
-
Alternative lengthening of telomeres and Ki-67 proliferation index provide complementary information on recurrence risk after resection of pancreatic neuroendocrine tumors. J Neuroendocrinol. 2025 04; 37(4):e70003.
-
DEK :: AFF2 Fusion Sinonasal and Skull Base Nonkeratinizing Squamous Cell Carcinoma : A Clinical Outcome Study Compared With Conventional Sinonasal Squamous Cell Carcinoma. Am J Surg Pathol. 2025 Feb 01; 49(2):130-137.
-
Utility of clinical and MR imaging parameters for prediction and monitoring of response to capecitabine and temozolomide (CAPTEM) therapy in patients with liver metastases of neuroendocrine tumors. Radiol Oncol. 2024 06 01; 58(2):196-205.
-
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 03 01; 10(3):362-371.
-
Neuroendocrine liver metastases treated using transarterial radioembolization: Identification of prognostic parameters at 68Ga-DOTATATE PET/CT. Diagn Interv Imaging. 2024 Jan; 105(1):15-25.
-
Survival and Symptomatic Relief After Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients. Ann Surg Oncol. 2023 Aug; 30(8):4840-4851.
-
Overview of Ancillary Techniques in Cervical Cytology. Acta Cytol. 2023; 67(2):119-128.